Literature DB >> 17047575

Motor fluctuations in Parkinson's disease.

William J Weiner1.   

Abstract

Parkinson's disease is characterized by progressive slowness in activities of daily living and is the most common cause of parkinsonism, whose symptoms include resting tremor, cogwheel rigidity, and bradykinesia. The introduction of levodopa and its positive effect on motor dysfunction in Parkinson's disease has allowed neurologists to focus on motor fluctuations. "End-of-dose wearing-off" and "morning akinesia" are terms to describe the transition between a patient's relatively normal motor performance when levodopa is effective and when it has transiently lost its effect on motor responses and parkinsonian symptoms reemerge. The choices available to alleviate these motor fluctuations range from altering the patient's levodopa/carbidopa dosing schedule to the addition of other agents to the regimen, including dopamine receptor agonists, catechol-O-methyltransferase inhibitors, monoamine oxidase inhibitors, and amantadine, as well as implementing dietary changes. Therapeutic decisions can be difficult because older agents have not been compared in head-to-head trials to determine which drugs are better than others and the order in which they should be tried or added to the levodopa regimen; however, all of the available treatments provide a good possibility of benefit to the patient. Deep brain stimulation surgery is an option for patients with medically intractable severe motor fluctuations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047575

Source DB:  PubMed          Journal:  Rev Neurol Dis        ISSN: 1545-2913


  8 in total

1.  Continuous in-home monitoring of essential tremor.

Authors:  C L Pulliam; S R Eichenseer; C G Goetz; O Waln; C B Hunter; J Jankovic; D E Vaillancourt; J P Giuffrida; D A Heldman
Journal:  Parkinsonism Relat Disord       Date:  2013-09-19       Impact factor: 4.891

2.  Monitoring motor fluctuations in patients with Parkinson's disease using wearable sensors.

Authors:  Shyamal Patel; Konrad Lorincz; Richard Hughes; Nancy Huggins; John Growdon; David Standaert; Metin Akay; Jennifer Dy; Matt Welsh; Paolo Bonato
Journal:  IEEE Trans Inf Technol Biomed       Date:  2009-10-20

3.  Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease.

Authors:  Ashley S Harms; Christopher J Barnum; Kelly A Ruhn; Steve Varghese; Isaac Treviño; Armin Blesch; Malú G Tansey
Journal:  Mol Ther       Date:  2010-10-19       Impact factor: 11.454

4.  Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease.

Authors:  Fábio G Teixeira; Miguel M Carvalho; Krishna M Panchalingam; Ana J Rodrigues; Bárbara Mendes-Pinheiro; Sandra Anjo; Bruno Manadas; Leo A Behie; Nuno Sousa; António J Salgado
Journal:  Stem Cells Transl Med       Date:  2016-09-22       Impact factor: 6.940

5.  Apomorphine in Parkinson's Disease-The Questions Raised.

Authors:  Rajinder K Dhamija; Achal K Srivastava; Divyani Garg
Journal:  Ann Indian Acad Neurol       Date:  2020-06-10       Impact factor: 1.383

6.  Stand-Alone Wearable System for Ubiquitous Real-Time Monitoring of Muscle Activation Potentials.

Authors:  Ivan Mazzetta; Paolo Gentile; Marco Pessione; Antonio Suppa; Alessandro Zampogna; Edoardo Bianchini; Fernanda Irrera
Journal:  Sensors (Basel)       Date:  2018-05-29       Impact factor: 3.576

7.  Multi-Dimensional, Short-Timescale Quantification of Parkinson's Disease and Essential Tremor Motor Dysfunction.

Authors:  John B Sanderson; James H Yu; David D Liu; Daniel Amaya; Peter M Lauro; Anelyssa D'Abreu; Umer Akbar; Shane Lee; Wael F Asaad
Journal:  Front Neurol       Date:  2020-09-18       Impact factor: 4.003

8.  Quantifying short-term dynamics of Parkinson's disease using self-reported symptom data from an Internet social network.

Authors:  Max Little; Paul Wicks; Timothy Vaughan; Alex Pentland
Journal:  J Med Internet Res       Date:  2013-01-24       Impact factor: 5.428

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.